CMS with Ypsomed a on the closing of the sale of its pen needle and BGM businesses to MTD
An international CMS team under the lead of Stefan Brunnschweiler (pictured left) and Florian Jung (pictured right) provided comprehensive advice to Ypsomed on all legal aspects regarding the completion of the sale of its pen needle and blood glucose monitoring systems (BGMs) businesses to Medical Technology and Devices (MTD) across 17 jurisdictions.
The sale of the pen needle and BGM businesses between Ypsomed and MTD was announced on 27 March 2024. The transaction is now legally completed after all conditions set out in the agreement have been fulfilled.
During a transition phase, Ypsomed will continue to produce pen needles as a contract manufacturer and provide services to enable a seamless transfer. The production facilities will be gradually relocated to the MTD sites by mid-2025. The space freed up will be used for a new toolmaking facility at the Solothurn site.
Ypsomed
Ypsomed is a developer and manufacturer of injection and infusion systems for self-medication and a renowned diabetes specialist. Ypsomed presents and markets its product portfolios under the umbrella brand mylife Diabetescare directly to patients, pharmacies, and hospitals as well as under Ypsomed Delivery Systems in business-to-business operations with pharmaceutical companies. Ypsomed is headquartered in Burgdorf, Switzerland. The company has a global network of production facilities, subsidiaries, and distribution partners with over 2,200 employees worldwide.
